Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Lung Neoplasms 1

Interventions

pembrolizumab 120Carboplatin 114Pemetrexed 74Cisplatin 71Nivolumab 68Paclitaxel 58Docetaxel 56Radiotherapy 41Erlotinib Hydrochloride 41Gemcitabine 35Etoposide 34atezolizumab 30osimertinib 29Cetuximab 27Ipilimumab 25Bevacizumab 25Radiosurgery 22durvalumab 21Cyclophosphamide 20Drug Therapy 18130-nm albumin-bound paclitaxel 17avelumab 14Taxes 14Gefitinib 14Albumin-Bound Paclitaxel 14Irinotecan 13Injections 13fludarabine 11Radiation 11cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × dalotuzumab × Thoracic × Clear all
NCT00869752 2023-08-04

MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Canadian Cancer Trials Group

Phase 1/2 Completed
12 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡